van de Waart P, Preissner K T, Bechtold J R, Müller-Berghaus G
Clinical Research Unit for Blood Coagulation and Thrombosis, Max-Planck-Gesellschaft, Justus-Liebig-Universität, Giessen, Federal Republic of Germany.
Thromb Res. 1987 Nov 15;48(4):427-37. doi: 10.1016/0049-3848(87)90400-2.
The physiological role of coagulation cofactor Protein S (PrS) for activated Protein C (APC) has recently been appreciated by the description of patients with PrS-deficiency, suffering from thromboembolism. The present study introduces a one-stage clotting assay for the assessment of PrS functional activity in plasma samples. The assay procedure is based on a factor Xa-initiated clotting test utilizing a mixture of AL(OH)3-adsorbed substrate plasma and patient's plasma supplemented with purified prothrombin (0.15 microM) and APC (0.05 microM), with phospholipids and CaCl2. Owing to the varying concentration of PrS in the sample plasma, clotting times were prolonged up to 25 seconds in the presence of APC, whereas no prolongation occurred in its absence. The test procedure proved to be specific for PrS, since preincubation with monospecific antibodies against PrS abolished the prolongation of clotting time, while reconstitution of adsorbed plasma with purified PrS restored its cofactor activity completely. The functional assay showed an inter-assay and intra-assay variation in the normal range of 11.7% and 10.1%, respectively (n = 20). PrS activity in a group of unselected patients (n = 34), revealing no abnormalities in global coagulation tests, amounted to 95.8 +/- 16.5% (mean +/- S.D.) with a range from 67% to 136% when analyzed in comparison to a plasma pool constituted from healthy volunteers. Patients (n = 32) undergoing oral anticoagulant therapy presented 21.1 +/- 10.8% residual PrS-activity accompanied by a concomitant decrease in PrS-antigen levels to 69.9 +/- 21.2%. The assay described is sensitive, it can be performed on routine basis and allows the detection of patients with PrS-deficiency.
凝血辅助因子蛋白S(PrS)对活化蛋白C(APC)的生理作用,最近通过对患有血栓栓塞的PrS缺乏症患者的描述而得到认识。本研究介绍了一种用于评估血浆样本中PrS功能活性的一步凝血试验。该试验程序基于一种由因子Xa启动的凝血试验,使用经氢氧化铝吸附的底物血浆和患者血浆的混合物,并补充纯化的凝血酶原(0.15微摩尔)和APC(0.05微摩尔),以及磷脂和氯化钙。由于样本血浆中PrS浓度不同,在有APC存在的情况下,凝血时间延长至25秒,而在其不存在时则无延长。该试验程序被证明对PrS具有特异性,因为用抗PrS单特异性抗体预孵育可消除凝血时间的延长,而用纯化的PrS重构吸附血浆可完全恢复其辅助因子活性。功能试验显示,批间和批内变异分别在正常范围的11.7%和10.1%(n = 20)。一组未经选择的患者(n = 34),其全血凝固试验无异常,与由健康志愿者组成的血浆池相比,PrS活性为95.8±16.5%(平均值±标准差),范围为67%至136%。接受口服抗凝治疗的患者(n = 32),PrS残余活性为21.1±10.8%,同时PrS抗原水平降至69.9±21.2%。所描述的试验很敏感,可在常规基础上进行,并能检测出PrS缺乏症患者。